In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medeus Deals Quickly for Skye's Depomorphine

Executive Summary

Newly-created Medeus Pharma hasn't waited long to sign its first in-licensing deal. Only two months after its creation, through the acquisition of Elan's European sales and marketing infrastructure, the firm has secured European rights to SkyePharma's sustained-release post-op pain treatment DepoMorphine for €100 million. SkyePharma continues shifting the source of its revenues from milestone payments to more predictable royalties; Medeus flexes its muscle as a viable, fast-moving competitor to larger pan-European in-licensers.
Advertisement

Related Content

Ex-Shire Team Builds New Euro-Specialty Group
Medeus: How To Find & Buy a Ready-Made Euro Infrastructure
The Pan European Licensing Opportunity
Delivering Profits at SkyePharma
Some Big Year-End Dealmaking From SkyePharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel